Trial Profile

Pivotal study of trehalose in patients with oculopharyngeal muscular dystrophy

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 14 Apr 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Trehalose (Primary)
Indications Oculopharyngeal muscular dystrophy
Focus Registrational; Therapeutic Use
Sponsors Seelos Therapeutics

Most Recent Events

14 Apr 2020 New trial record
08 Apr 2020 According to a Seelos Therapeutics media release, the company s working on finalizing a protocol for a pivotal study in Oculopharyngeal Muscular Dystrophy (OPMD) and expects to provide details after interacting with the FDA.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com